Бегущая строка

SSFI $21.91 0.2976%
XEKT.MC $62.50 3.3058%
0KTI.L $52.41 -1.5035%
CASH.L $16.05 -0.8803%
DGE.L $3 534.50 -2.3484%
CS $0.84 -0.4013%
SF-PB $22.78 0.953%
0LVK.L $113.40 -0.7309%
0JQ4.L $109.40 0%
0A1V.L $48.96 -1.2141%
MCPHY.PA $11.08 -0.983%
NOAC $10.06 0%
HCP $31.21 -3.0745%
DYHG $61.24 0%
ETW $8.07 -0.2472%
DPST $3.89 -2.75%
GFX $10.13 -0.0986%
MTW.L $635.00 0%
MNOV $2.18 0.9259%
USAC $19.10 0.4734%
ALDBL.PA $3.40 -10.5263%
KSCD $25.64 0%
8295.HK $0.07 -8.1081%
IMRN $2.27 -9.048%
ABCA.PA $6.02 -0.6601%
FPN.PA $0.03 0%
FNDA $46.04 -0.7653%
SBTX.L $17.38 -5.4422%
CVI $23.51 -3.251%
BCACU $23.20 0%
0I2P.L $36.66 -0.0954%
0823.HK $49.55 -0.9%
ASTC $10.94 -0.1178%
GFRD.L $179.40 -0.5543%
NCVLX $12.56 0.0797%
INFU $9.00 0.3512%
0028.HK $4.13 0.978%
PODP.L $79.00 -5.8403%
WHLR $0.85 1.1905%
6190.HK $9.54 0%
1868.HK $0.42 0%
SWP.PA $41.00 0%
HLF $14.18 -3.2423%
AENA.MC $152.05 1.6717%
HSBC $37.40 -0.1469%
COPX.L $26.94 0.092%
IGIB $51.05 -0.4291%
PHTM.L $77.20 0%
ZVIA $3.38 0.5952%
POWE3.SA $10.90 0%
GLOG.BR $4.90 0%
SIXO $26.36 -0.2841%
SCI $65.50 -0.7876%
FSRDW $0.01 0%
0184.HK $2.60 0.3861%
LMAT $65.05 -0.1841%
ALPA3.SA $9.33 0%
CNFRL $23.35 0.4301%
BIDI11.SA $10.40 0%
MDO.L $2.06 0%
NRIX $10.13 -0.4912%
0J3K.L $60.90 1.5826%
IBDX $24.90 -0.42%
CIC.L $115.00 -0.8621%
BPYU $18.52 0%
MULG $7.00 0%
BHB $22.41 -0.8189%
MNRO $48.83 0.5353%
0P000185T0.L $15 958.80 -0.1152%
CHKP $120.45 -0.364%
OTMO $0.44 0%
0P00017UWP.L $15 749.60 0.2661%
VGPA.L $43.80 0.3609%
DUNE $9.96 0.1005%
CHAR.L $16.38 0.6761%
PVH $83.11 0.2896%
IT $310.55 1.5367%
PNW $80.44 -0.149%
OTRAU $9.55 0%
CNS.L $6.65 0%
VEGN $34.46 0.3749%
NQP $11.21 -0.3644%
NX $19.78 -1.6899%
MIST $4.33 1.8824%
CORN $22.74 -0.9582%
AGZD $43.44 0.0583%
CREE $79.12 0%
0I6U.L $22.91 0.357%
1446.HK $0.30 1.6949%
UAA $7.53 -1.634%
ISCV $49.36 -0.3963%
NXT.L $6 818.00 -0.4962%
TRIA.L $42.09 0%
0653.HK $0.12 0%
CHPMU $10.15 0%
MXUS.L $115.82 -0.1466%
LWI.L $123.50 -0.8032%
BOTJ $9.10 2.3622%
CAF.PA $67.70 -2.1818%
IDRV $36.95 -1.7287%

Хлебные крошки

Акции внутренные

Лого

Cosmo Pharmaceuticals N.V. 0RGI.L

$52.00

-$0.71 (-1.36%)
На 18:02, 12 мая 2023

Ключевые показатели

  • Marketcap

    7734204.00000000

  • week52high

    69.40

  • week52low

    42.60

  • Revenue

  • P/E TTM

    0

  • Beta

    1.07022900

  • EPS

    1.30500000

  • Last Dividend

    0.28500000

  • Next Earnings Date

    07 мая 2023 г. в 04:04

Описание компании

Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.

Свежие комментарии

Свежие комментарии

Оставьте свой голос

Оставьте свой голос

Анонимное голосование

Будет ли рост российского рынка к концу года?

  • Да

    87%
  • Нет

    12%

Проголосовал 8 человек